SCLX

Scilex Holding Company
CAPPED RATING

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Scilex Holding Company (SCLX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Momentum (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
B
Factor Score 3.4 / 5.0
Growth
D
Factor Score 1.3 / 5.0
Profitability
C+
Factor Score 2.5 / 5.0
Momentum
D-
Factor Score 0.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 2.0
EV / EBITDA -0.4
Rev Growth YoY -22.8%
Gross Margin 55.5%
Price Return 3M -77.7%
Price Return 12M -87.9%
Catalyst Signal 0.00
Market Cap $10.1M
TTM Revenue $31.6M
Price / Sales 0.3
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B (3.4) D (1.3) C+ (2.5) D- (0.9) C+ (2.6) C (2.2)
2026-11-07 B (3.4) D (1.3) C+ (2.6) D- (0.8) C+ (2.7) C- (2.1)
2026-10-31 B (3.4) D (1.2) C+ (2.6) D- (0.9) C+ (2.7) C (2.2)
2026-10-24 B (3.4) D (1.2) C+ (2.6) D+ (1.7) C+ (2.6) C (2.3)
2026-10-17 B (3.3) D (1.2) C+ (2.6) D+ (1.8) C+ (2.6) C (2.3)
Page 1 of 3